Dechra Pharmaceuticals plc 22.3% potential upside indicated by Deutsche

Dechra Pharmaceuticals plc with ticker (LON:DPH) now has a potential upside of 22.3% according to Deutsche.



Deutsche set a target price of 4,070 GBX for the company, which when compared to the Dechra Pharmaceuticals plc share price of 3,328 GBX at opening today (31/05/2023) indicates a potential upside of 22.3%. Trading has ranged between 2,473 (52 week low) and 4,000 (52 week high) with an average of 1,200,603 shares exchanging hands daily. The market capitalisation at the time of writing is £3,835,616,488.

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company’s segments include European Pharmaceuticals, NA Pharmaceuticals, and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment comprises of Dechra Veterinary Products EU, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing & Supply. This Segment operates internationally and manufactures and markets Companion Animal Products (CAP), Equine, Food producing Animal Products (FAP) and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Dechra Veterinary Products Canada, and Dechra Productos Veterinarios (Mexico), which sell CAP, Equine and FAP in those territories. The Segment also includes its manufacturing units based in Melbourne, Florida and Fort Worth, Texas. The Pharmaceuticals Research and Development Segment includes all of the Company’s pharmaceutical research and development activities.